S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

GILD Gilead Sciences Inc

92.275

-1.84 (-1.95%)

Last Updated: 05:18:40

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2024 to Dec 2024

Click Here for more Gilead Sciences Charts.

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Gilead Sciences Charts.

Gilead Sciences Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 24 December 2024 (7 days ago) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 24 December 2024 (7 days ago) • Edgar (US Regulatory)

Gilead Sciences to Present at Upcoming Investor Conference
Saturday 21 December 2024 (1 week ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 20 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 18 December 2024 (2 weeks ago) • Edgar (US Regulatory)

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Wednesday 18 December 2024 (2 weeks ago) • Business Wire

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Tuesday 17 December 2024 (2 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 17 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Friday 13 December 2024 (2 weeks ago) • Business Wire

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Friday 13 December 2024 (3 weeks ago) • Business Wire

More Gilead Sciences Inc News Articles

Perp.trust'a'4a

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions